Interleukin 6 (IL6) Antibody
234€ (50 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Interleukin 6 (IL6) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx125159
tested applications
WB, IHC, CLIA
Description
Interleukin 6 (IL6) Antibody is a Mouse Monoclonal antibody against Human Interleukin 6 (IL6).
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Interleukin 6 (IL6) |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | Validated in IHC-P. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG1 |
| Purification | Purified from mouse ascites by Protein G chromatography. |
| Size 1 | 50 µg |
| Size 2 | 100 µg |
| Form | Liquid |
| Tested Applications | WB, IHC, CLIA |
| Buffer | PBS, pH 7.4. |
| Availability | Shipped within 5-12 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P05231 |
| Alias | IL-6,BSF,HGF,HSF,IFNB2,CDF,B-cell stimulatory factor 2 |
| Background | Antibody anti-IL6 |
| Status | RUO |
| Note | Concentration: 2.84 mg/ml - |
Descripción
IL6 is a pleiotropic cytokine involved in regulating immune responses, inflammation, and hematopoiesis It is produced by macrophages, T cells, fibroblasts, and endothelial cells in response to infections, trauma, or tissue damage IL6 activates downstream signaling through its receptor, IL-6R, and the JAK/STAT3 pathway, driving acute-phase protein synthesis, such as CRP and fibrinogen, and promoting B cell differentiation into plasma cells Dysregulated IL6 expression is associated with chronic inflammation, autoimmune diseases like rheumatoid arthritis, and cancer progression, where it promotes tumor growth, survival, and angiogenesis IL6 also contributes to cytokine storm syndrome in conditions like COVID-19, where excessive IL6 leads to hyperinflammation and organ damage Targeting IL6 signaling with anti-IL6 therapies, such as tocilizumab, has shown efficacy in treating autoimmune diseases and cytokine-driven conditions
Related Products
APC Anti-Human IL-6(MQ2-13A5)
Ver Producto
Human HS-IL-6 (High sensitive Interleukin 6) high sensitive Accquant ELISA Kit
Ver Producto